Joanna Khatib, MD
Endocrinology, Diabetes & Metabolism · Millsboro, DENPI 1306227400
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,109 of the $6,845 with a category attached, or 89.3%. 42 manufacturers reported payments, led by Novo Nordisk at 29.5% of the total.
Across 270 payments — averaging $25.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$479
- Abbott$467
- Amgen$425
- AbbVie$365
- Pfizer$284
- plus $3K from 36 others
What the payments were for
- Travel & lodging$71110%
- Food & beverage$6,10989%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$122
- TZIELD$112
- DEXCOM G6 TRANSMITTER$106
How this compares
$6,845 in reported general payments places this provider in the 85th percentile of 30 endocrinology, diabetes & metabolism providers in Delaware.
See all endocrinology, diabetes & metabolism providers in Delaware →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 538 | $1,035,670 |
| JardianceEmpagliflozin | 301 | $406,512 |
| TrulicityDulaglutide | 214 | $384,633 |
| MounjaroTirzepatide | 193 | $371,081 |
| FarxigaDapagliflozin Propanediol | 92 | $131,318 |
| Tresiba Flextouch U-100Insulin Degludec | 116 | $92,534 |
| RybelsusSemaglutide | 52 | $89,221 |
| Tresiba Flextouch U-200Insulin Degludec | 49 | $87,703 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 41 | $83,585 |
| JanuviaSitagliptin Phosphate | 51 | $71,675 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $70,139 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 40 | $64,243 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 84 | $51,462 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 18 | $33,806 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 197 | $31,929 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $2,020 | $1,132,490616 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $479 | $759,936422 claims |
| Boehringer IngelheimJardiance, Tradjenta | $177 | $431,761332 claims |
| AstraZenecaFarxiga | $170 | $131,31892 claims |
| MerckJanuvia, Janumet Xr | $35 | $92,68064 claims |
| AbbVieSynthroid | $365 | $25,400295 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $82 | $6,600590 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 30 endocrinology, diabetes & metabolism providers in Delaware.
Other endocrinology, diabetes & metabolism in Millsboro
- Ahmad ElayyanMillsboro$4K
- Abhigna KulkarniMillsboro$2K
- Ripudaman HundalNewark$370K
- Nira MadisiMilford$23K
- Francisco PadillaSeaford$22K
- Reetu SinghLewes$9K
- Chitra ChoudharyDover$5K
- Sheetal BulchandaniNewark$4K
- Avinash RavipatiLewes$3K
- Marc LaufgrabenNewark$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.